These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [In vitro activity of telithromycin against community acquired respiratory pathogens].
    Author: Ulloa F MT, Camponovo C R, Fernández V A, García C P, Prado J V, González A P, Rojas S P, Inostroza S J, Lafourcade R M, Aguilera A L, Porte T L, Cruz P C, Joyas M A, Alcaide L B, Pinto C ME, Giglio M MS.
    Journal: Rev Med Chil; 2005 Apr; 133(4):419-25. PubMed ID: 15953948.
    Abstract:
    BACKGROUND: Telithromycin is a new ketolide antimicrobial, that can be useful for the treatment of respiratory infections. AIM: To compare in vitro activity of telithromycin against respiratory pathogens, isolated in outpatient clinics. MATERIAL AND METHODS: Two hundred eighty strains isolated from patients with respiratory infections, were studied. The strains studied were S pneumoniae, penicillin sensitive (SPNS:57); intermediate (SPNI:35), resistant (SPNR:25); S pyogenes (SP:57); H influenzae (HIN 51); M catarrhalis (MC:25) and S aureus meticillin sensitive (SAUS:30). Minimal inhibitory concentration (MIC) by broth microdilution was studied for telitrhomycin and levofloxacin in all strains. Other antimicrobials studied, but not in all strains were erythromycin, clindamycin, trimetoprim sulphamethoxazole, oxacillin, amoxicillin-clavulanic acid and cefuroxime. RESULTS: All strains were sensible to telithromycin at a concentration -4 microg/ml. MIC 90 and its range for SPNS was 0.03 microg/ml (-0.004-0.12), for SPNI was 0.03 microg/ml (-0.004-025), for SPNR was 0.06 microg/ml (-0.004-0.25), for HIN was 2 microg/ml (0.12-4), for SP was 0.5 microg/ml (-0.004-2), for MC was 0.5 microg/ml (0.06-2) and for SAU was 0.25 microg/ml (0.06-0.25). CONCLUSIONS: All studied pathogens were sensible to telithromycin in vitro. This antimicrobial is an alternative for the treatment of community acquired respiratory infections.
    [Abstract] [Full Text] [Related] [New Search]